30
Participants
Start Date
October 11, 2013
Primary Completion Date
February 27, 2014
Study Completion Date
February 27, 2014
FF/LEV FDC
Intranasal aqueous microsuspension containing 25.0 microgram (µg) of FF and 50 µg of LEV as a fixed dose combination. It will be administered as two 50 µL sprays per nostril in the morning in a fasted state
FF
Intranasal aqueous microsuspension containing 27.5µg of FF. It will be administered as two 50 µL sprays per nostril in the morning in a fasted state
LEV
Intranasal aqueous microsuspension containing 50 µg of LEV. It will be administered as two 50 µL sprays per nostril in the morning in a fasted state
GSK Investigational Site, Randwick
Lead Sponsor
GlaxoSmithKline
INDUSTRY